Future directions in systemic treatment of metastatic hormone-sensitive prostate cancer

Chen, K; Kostos, L; Azad, AA

Author(s): Chen, K; Kostos, L; Azad, AA;
Details: Publication Year 2023-08,Volume 41,Issue #8,Page 2021-2031
Journal Title: World Journal of Urology
Publication Type: Review
Abstract: The landscape of advanced prostate cancer treatment has evolved tremendously in past decades. The treatment paradigm has shifted from androgen deprivation therapy (ADT) alone to doublet combinations comprising ADT with docetaxel or an androgen receptor inhibitor, and now triplet therapy involving all 3 classes of agents. Robust clinical data has demonstrated survival benefits with this strategy of upfront treatment intensification. Subgroup analysis has alluded to the importance of tailoring treatment according to metastatic disease burden. However, defining the volume of disease is becoming increasingly controversial due to the advent of next generation molecular imaging. Several trials testing established agents in the castrate-resistant setting are now underway in metastatic hormone sensitive prostate cancer patients. As the treatment milieu is enriched earlier in the disease trajectory, future studies should elucidate biomarkers to further define specific patient populations who will benefit most from treatment intensification and/or de-escalation, with what agents and for what duration.
Publisher: Springer Nature
Keywords: Male; Humans; *Prostatic Neoplasms/pathology; Androgen Antagonists/therapeutic use; Docetaxel/therapeutic use; Hormones/therapeutic use; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Advanced prostate cancer; Androgen pathway receptor inhibitors; Combination treatment; Prostate cancer; Treatment intensification
Department(s): Medical Oncology
PubMed ID: 36029329
Publisher's Version: https://doi.org/10.1007/s00345-022-04135-8
Open Access at Publisher's Site: https://doi.org/10.1007/s00345-022-04135-8
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2023-10-25 06:30:01

Last Modified: 2023-10-25 06:33:22